Role of adrenergic neuronal activity in the yawning induced by tacrine and NIK-247 in rats.
The present experiments were performed to investigate the potential role of central adrenergic neurons in regulating occurrence of yawning in rats. Intraperitoneal injection of tacrine (THA) or 9-amino-2,3,5,6,7,8-hexahydro-1H-cyclopenta(b)-quinoline monohydrate HCl (NIK-247), cholinesterase inhibitors, induced yawning, which was markedly increased by pretreatment with the beta-adrenoceptor antagonist, pindolol. The yawning evoked by tacrine or NIK-247 given alone or in combination with pindolol was inhibited by pretreatment with scopolamine but not by mecamylamine or spiperone. Treatment with tacrine or NIK-247 increased acetylcholine content of the striatum, but this effect was not enhanced by pindolol, which per se did not affect basal acetylcholine content. Moreover, pretreatment with the central adrenaline synthesis inhibitors, (+-)-2,3-dichloro-alpha-methylbenzylamine HCl (LY-78335) and 2-cyclooctyl-2-hydroxyethylamine HCl (UK-1187A), increased tacrine-induced yawning. Subcutaneous injection of talipexole (B-HT 920), a dopamine D2 receptor agonist, evoked yawning, which was also increased by pindolol, LY-78335, and UK-1187A. These receptors antagonists and synthesis inhibitors per se did not cause yawning responses. The results suggest that the beta-adrenoceptor blockade and the inhibition of adrenaline synthesis facilitate the occurrence of yawning induced by cholinergic and dopaminergic agonists, and thus the central adrenergic neuronal systems may be implicated in the regulation of yawning responses.
Department of Pharmacology, School of Medicine, Fukuoka University, Japan.
H
H
Kimura
K
K
Yamada
M
M
Nagashima
S
S
Matsumoto
Y
Y
Ishii
S
S
Yoshida
K
K
Fujii
T
T
Furukawa
D000109:Acetylcholine / Q000378:metabolism; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000634:Aminoquinolines / Q000494:pharmacology*; D000818:Animals; D001381:Azepines / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D002800:Cholinesterase Inhibitors / Q000494:pharmacology*; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D015259:Dopamine Agents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D008297:Male; D009474:Neurons / Q000502:physiology*; D011619:Psychotropic Drugs / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D011956:Receptors, Cell Surface / Q000037:antagonists & inhibitors; D013564:Sympathetic Nervous System / Q000502:physiology*; D013619:Tacrine / Q000494:pharmacology*; D015000:Yawning / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D000634:Aminoquinolines; D001381:Azepines; D002800:Cholinesterase Inhibitors; D015259:Dopamine Agents; D011619:Psychotropic Drugs; D011943:Receptors, Adrenergic, beta; D011956:Receptors, Cell Surface; D013619:Tacrine; C024763:talipexole; C049860:amiridine; D000109:Acetylcholine